Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy
详细信息 查看全文
- 作者：Julian Borchardta ; julian.borchardt@gmx.de" class="auth_mail" title="E-mail the corresponding author ; Joseph R. Bergerb
- 关键词：Progressive multifocal leukoencephalopathy (PML) ; Natalizumab (Tysabri) ; Risk-stratification algorithm ; L-selectin (CD62L) ; CSF lipid-specific IgM bands ; JCV antibody index
- 刊名：Multiple Sclerosis and Related Disorders
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：8
- 期：Complete
- 页码：145-150
- 全文大小：393 K
文摘
- •
Realistic estimates of the longterm risk of PML are almost double the published figures.
- •
The risk with a JCV index of 1.1 and no prior IS use is 9 times higher than previously thought.
- •
Current risk-stratification remains a gamble even with the proper inclusion of the JCV index.
- •
The 0.9 JCV index cutoff promoted as a means of avoiding most PML cases is too optimistic.
- •
We present statistically significant evidence that JCV serology testing has been valuable.